U.S., Dec. 13 -- ClinicalTrials.gov registry received information related to the study (NCT07280299) titled 'Efficacy, Safety, Tolerability, and Biomarker Effects of GT-02287 in Early Parkinson's Disease' on Nov. 24.
Brief Summary: The purpose of this study is to assess the efficacy, the safety, and the effect on biomarkers of 2 dose levels of oral GT-02287 over placebo after 48 weeks of treatment in treated and untreated participants with early PD.
Study Start Date: May 30, 2026
Study Type: INTERVENTIONAL
Condition:
Parkinson Disease
Intervention:
DRUG: Low Dose GT-02287
Sachets containing 400 mg/day or 600 mg/day of active (GT-02287), depending on the participant's body weight. Each daily dose will be prepared as an oral suspensio...